CLENIL 250mcg price in UAE

Overview

Welcome to Dwaey, specifically on CLENIL 250mcg Inhaler/Aerosol page.
This medicine contains an important and useful components, as it consists of Beclomethasone dipropionate.
CLENIL 250mcg is available in the market in concentration 250mcg/Dose and in the form of Inhaler/Aerosol.

CHEISI FARMACEUTICI S.p.A. is the producer of CLENIL 250mcg and it is imported from ITALY, The most popular alternatives of CLENIL 250mcg are listed downward .

Mode Of Action

Beclometasone controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes, fibroblasts, reverses capillary permeability and lysosomal stabilisation at the cellular level to prevent or control inflammation.

Indication

Asthma
Chronic obstructive pulmonary disease (COPD)

Precaution

Patients should be instructed to use inhaler properly to ensure that the drug reaches the target areas within the lungs. They should also be made aware of the prophylactic nature of therapy with Beclometasone Dipropionate HFA inhaler and that they should use it regularly, even when they are asymptomatic. Intranasal corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. Beclometasone dipropionate is not suitable for the treatment of an acute asthma attack. Lactation: Potential for excretion into milk; use only if benefits greatly outweigh risks

Side Effects

>10% Pharyngitis (5-27%)
Headache (8-25%)
URI (5-11%) 1-10% Rhinitis (3-7%)
Pain (1-5%)
Increased asthma symptoms (2-4%)
Dysphonia (1-4%)
Sinusitis (3%)
Oral symptoms (2-3%)
Nausea (1-2%)

Contra indication

Hypersensitivity to any of the ingredients of this preparation contraindicates its use. Child under 6 years not recommended.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Inhibitors of CYP3A4: potential pharmacokinetic interaction (increased plasma beclomethasone dipropionate concentrations). Inducers of CYP3A4: potential pharmacokinetic interaction (decreased plasma beclomethasone dipropionate concentrations). Antidiabetic agents May increase blood glucose concentrations in patients with diabetes mellitus. NSAIDs Possible increased risk of GI ulcerationa Decreased serum salicylate concentrations. When corticosteroids are discontinued, serum salicylate concentration may increase possibly resulting in salicylate intoxication Vaccines and Toxoids May cause a diminished response to toxoids and live or inactivated vaccines. May potentiate replication of some organisms contained in live, attenuated vaccines. Can aggravate neurologic reactions to some vaccines (supraphysiologic dosages).